PROFILE AND COMPLEXITY LEVEL OF CLINICAL TRIALS IN THE PHARMACY SERVICE
5PSQ-091
ASTHMA IN THE MOROCCAN POPULATION
5PSQ-090
ANTICHOLINERGIC DRUGS AND ACETYLCHOLINESTERASE INHIBITORS: A NON-RECOMMENDED COMBINATION
5PSQ-089
PREVALENCE OF PRESCRIPTION OF ANTIPSYCHOTIC POLYPHARMACY IN A PSYCHIATRIC HOSPITAL
5PSQ-088
DEVELOPMENT OF ALZHEIMER'S DISEASE AND EXPOSITION TO BENZODIAZEPINES: A COHORT STUDY IN A HEALTH REGION OF CATALONIA BETWEEN 2002 AND 2015
5PSQ-087
INAPPROPIATE USE OF HYDROXYCINE
5PSQ-086
PREVALENCE OF ASPIRATION PNEUMONIA FOLLOWING ANTIPSYCHOTICS: A LARGE POPULATION STUDY
5PSQ-085
METABOLIC DISORDERS IN PATIENTS TREATED WITH SECOND-GENERATION ANTIPSYCHOTICS: AN OPPORTUNITY FOR PHARMACEUTICAL INTERVENTION
5PSQ-084
RISK OF QT INTERVAL PROLONGATION IN OLDER PATIENTS
5PSQ-083
DEVELOPMENT AND VALIDATION OF QUALITY INDICATORS FOR BENZODIAZEPINE USE IN GENERAL AND MENTAL HEALTH HOSPITALS: SHORTCOMINGS OF AVAILABLE REIMBURSEMENT DATA
5PSQ-082
ABSTRACT WITHDRAWN
5PSQ-081
Δ-9-TETRAHYDROCANNABINOL(SATIVEX) FOR THE TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY: EVALUATION OF EFFECTIVENESS AND SAFETY
5PSQ-080
A STUDY ON RISK FACTORS ELICITING OPIOID ADVERSE REACTIONS IN ELDERLY MALES
5PSQ-079
THE USE OF FENTANYL SUBLINGUAL TABLETS IN A HOSPITAL
5PSQ-078
MORPHINE OVERDOSE FROM ERROR INFUSION RATE WITH INTRAVENOUS PUMP: FEEDBACK EXPERIENCE AND ACTION PLAN
